Loading
LD
LDX Stock: price and insider trades · Australia
No insider purchase over the last 90 days. The latest was filed 18 Jun 2026.
LDX: what insiders have been doing
LDX is a Health Care company. Its directors and officers file their transactions with ASX. 3 insiders have disclosed 5 filings since 18 October 2025.
The flow runs one way only: 2 insiders bought (3 purchases totalling €38k) and nobody sold on the market. No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €19k, the purchase published on 18 June 2026 is the largest of the period. Those buying include 2 senior executives.
The last purchase on record was published on 18 June 2026, which is 121 days ago.
Compared with its exchange (2,520 companies, median 2 filings), a count of 5 filings is above the norm. Over the whole record (from 2026), the tally stands at 3 purchases and no sales.
For comparison within the same sector, see the insider buying recorded at MAIA Biotechnology, Inc. and Cooper Companies, Inc. Source: insider filings from ASX. Past trades are no guide to future returns.
Insider Decl.
5
Thresholds
n/a
Buy Volume
€37,613
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleUnknown2 buys
Doug Ward1 buy
Since the insiders bought
- -6.7%Entry A$0.10 · Close 12 Oct 2026 A$0.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate LDX Strong Buy (bullish), based on 2 analysts. Average price target: A$0.30.
Fundamental score
Ranked 19,994 of 24,148 companies
28.6
score / 100
Value26
Quality31
FCF yld-1.5%
Earn yld-4.9%
EV/EBITDA·
ROE-34%
Gross mgn60%
Net mgn-38%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
A$0.11
Analyst consensus
2 analystsStrong buy
A$0.25Target A$0.30(+186%)A$0.35
Income statement
RevenueA$13.2M
Gross profitA$7.9M60% margin
EBITDA-A$850k-6% margin
Net income-A$5M-37.5% margin
Valuation
PER (forward)-7.5x
P/Book3.1x
Beta0.54
Balance sheet & cash
Market capA$102M
Total debtA$5.9M
Free Cash Flow-A$1.5M
Debt / Equity26%
Profitability & ownership
ROE-34.1%
ROA-28.7%
% insiders21.0%
% institutions19.8%
Last declaration on 13 October 2026
About LDX
LDX is a company operating in the health and pharmaceutical sector, listed on the XASX. It focuses on developing innovative solutions to enhance patient health.
